Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Cancer

Show all topics

DOI

10.1093/annonc/mdz127

License

CC-BY-NC

Other Formats

PDF